Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence — Stella
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(33 sites)
United States
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Siteman Cancer Center at Washington University, St Louis, Missouri
M D Anderson Cancer Center, Houston, Texas
France
Institut de Cancérologie de l'Ouest (ICO), Angers
CHU Angers, Hôpital Larrey, Angers
CHU Besançon, Hôpital Jean Minjoz, Besançon
CHU Brest, Hôpital La Cavale Blanche, Brest
Centre Georges François Leclerc, Dijon
Lyon HCL, Lyon
HCL Hôpital Louis Pradel, Lyon
Marseille Hôpital Nord, Marseille
Marseille Hôpital de la Conception, Marseille
CHU Nantes, Hôpital René et Guillaume Laënnec, Nantes
CHU Nantes, Hôpital René et Guillaume Laënnec, Nantes
Hôpital Cochin, AP-HP, Paris
Hôpital Cochin, AP-HP, Paris
Hôpital Cochin, Paris
Germany
LMU Klinikum München, Munich
Universitätsklinikum Würzburg, Würzburg
Poland
Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice